SARS-CoV-2 causes a phenotype of pneumonia with diverse manifestation, which is termed as coronavirus disease 2019 (COVID-19). An impressive high transmission rate allows COVID-19 conferring enormous challenge for clinicians worldwide, and developing to a pandemic level. Combined with a series of complications, a part of COVID-19 patients progress into severe cases, which critically contributes to the risk of fatality. To date, coagulopathy has been found as a prominent feature of COVID-19 and severe coagulation dysfunction may be associated with poor prognosis. Coagulopathy in COVID-19 may predispose patients to hypercoagulability-related disorders including thrombosis and even fatal vascular events. Inflammatory storm, uncontrolled inflammation-mediated endothelial injury and renin angiotensin system (RAS) dysregulation are the potential mechanisms. Ongoing efforts made to develop promising therapies provide several potential strategies for hypercoagulability in COVID-19. In this review, we introduce the clinical features of coagulation and the increased vascular thrombotic risk conferred by coagulopathy according to present reports about COVID-19. The potential underlying mechanisms and emerging therapeutic avenues are discussed, emphasizing an urgent need for effective interventions.

SARS-CoV-2 引起具有多种表现的肺炎表型，称为冠状病毒病 2019 (COVID-19)。令人印象深刻的高传播率使 COVID-19 给全世界的临床医生带来巨大挑战，并发展到大流行的程度。结合一系列并发症，部分 COVID-19 患者进展为重症病例，这严重增加了死亡风险。迄今为止，已发现凝血病是 COVID-19 的一个突出特征，严重的凝血功能障碍可能与预后不良有关。COVID-19 的凝血功能障碍可能使患者易患高凝状态相关疾病，包括血栓形成甚至致命的血管事件。炎炎风暴，不受控制的炎症介导的内皮损伤和肾素血管紧张素系统 (RAS) 失调是潜在的机制。为开发有前途的疗法所做的持续努力为 COVID-19 的高凝状态提供了几种潜在的策略。在这篇综述中，我们根据目前关于 COVID-19 的报道，介绍了凝血的临床特征以及凝血病导致的血管血栓形成风险增加。讨论了潜在的潜在机制和新兴的治疗途径，强调迫切需要有效的干预措施。根据有关 COVID-19 的现有报告，我们介绍了凝血的临床特征以及凝血病导致的血管血栓形成风险增加。讨论了潜在的潜在机制和新兴的治疗途径，强调迫切需要有效的干预措施。根据有关 COVID-19 的现有报告，我们介绍了凝血的临床特征以及凝血病导致的血管血栓形成风险增加。讨论了潜在的潜在机制和新兴的治疗途径，强调迫切需要有效的干预措施。